Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Oct 15, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating a protein called DKK2 to understand how it relates to patients who have experienced an ischemic stroke, which happens when blood flow to the brain is blocked. The researchers want to see how DKK2 levels in the blood change after patients receive a specific treatment to restore blood flow and how these levels might link to patient recovery. The study is currently recruiting participants aged 18 to 80 who have had a diagnosed acute ischemic stroke and meet certain medical criteria.

To participate, individuals should have a clear diagnosis of ischemic stroke and show signs of a large vessel blockage in the front part of the brain. Participants will need to agree to the treatment and sign consent forms. Those with certain medical conditions, previous stroke complications, or recent surgeries will not be eligible. If you join the study, you can expect to have your blood levels tested regularly and receive follow-up care to monitor your recovery. This research aims to improve understanding of stroke recovery and potentially help future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years, \< 80 years, sex not limited;
• • 2. Definite clinical diagnosis of acute ischemic stroke;
• • 3. Baseline NIHSS score ≥ 6 and ≤ 25;
• • 4. CTA/MRA/DSA examination suggests large vessel occlusion in the anterior circulation (internal carotid artery, M1/M2 segment of the middle cerebral artery);
• • 5. The criteria for receiving endovascular treatment in accordance with the Chinese Guidelines for Early Endovascular Intervention in Acute Ischemic Stroke 2018 and have successful revascularization (TICI ≥ grade 2b);
• • 6. Subjects or their legal representatives agree to the treatment and sign the informed consent form.
• Exclusion Criteria:
• • 1. Patients with combined posterior circulation infarction;
• • 2. The mRS ≥ 2 points before the current episode;
• • 3. Patients who are to be treated with or have been treated with anticoagulants;
• • 4. Patients with existing or active organ bleeding within 6 months of enrollment, including cerebral hemorrhage, subarachnoid hemorrhage, gastrointestinal tract hemorrhage, fundus hemorrhage, etc;
• • 5. The presence of other intracranial pathologies, such as cerebrovascular malformations, cerebral venous lesions, tumors, and other diseases involving the cranium;
• • 6. Severe organ dysfunction or failure;
• • 7. Those with severe hematologic disorders or severe coagulation abnormalities；
• • 8. Those with a history of severe trauma or major surgical procedures within 6 months prior to enrollment;
• • 9. Pregnant or lactating women;
• • 10. Patients with a life expectancy of less than 3 months or who for other reasons are unable to complete the study;
• • 11. Unwillingness to be followed up or poor compliance with treatment;
• • 12. Other conditions that the investigator considers unsuitable for enrollment.